How to access Skyrizi from Qatar — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Qatari patient with moderate-to-severe plaque psoriasis, psoriatic arthritis, or moderately-to-severely active Crohn's disease may receive a prescription for Skyrizi (risankizumab) from their treating dermatologist, rheumatologist, or gastroenterologist. Skyrizi is FDA-approved in the United States and manufactured by AbbVie. Access through Qatari hospital pharmacies varies by indication and supply timing — when your indication is not on a local formulary, or the exact dose form you need is not in stock, the named-patient import pathway is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Skyrizi is a humanised IgG1 monoclonal antibody that selectively inhibits IL-23 via binding the p19 subunit. For plaque psoriasis and psoriatic arthritis it is a subcutaneous injection on a quarterly maintenance schedule after two loading doses; for Crohn's disease it uses an IV induction followed by subcutaneous maintenance. Your treating physician confirms eligibility (severity documentation, endoscopic activity for IBD), TB screening, and the monitoring plan per FDA labeling.
Is Skyrizi legally importable into Qatar?
Yes — through the Qatar Ministry of Public Health (MoPH) Pharmacy & Drug Control Department named-patient framework. The pathway allows a Qatar-licensed physician to import a medicine not locally registered for the specific indication or dose form when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
Skyrizi is registered in many Gulf markets for plaque psoriasis; the Crohn's indication and specific paediatric or induction-dose forms are where named-patient imports most often come in.
How the pathway works, step by step
- Consultation with your treating physician. Severity documentation, endoscopic activity if IBD, and clinical rationale.
- Confirming the import rationale. Indication, dose form, or supply-gap rationale is documented.
- MoPH named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Cold-chain shipment. Skyrizi ships at 2–8°C with continuous temperature monitoring.
- Arrival and first dose. The dispensing facility releases product for in-clinic or at-home administration after training.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Skyrizi as the indicated treatment
- Verification of their Qatar medical licence
- Patient identifier
- TB/infection screening confirmation
- Planned loading/maintenance regimen
Reserve Meds provides a physician documentation kit that bundles the templates MoPH reviewers expect to see for IL-23-class biologics.
Costs and timing
Skyrizi's US cash-pay reference price for a 150 mg maintenance dose sits in a broad indicative range of roughly USD 18,000–22,000; the Crohn's IV induction dose is priced separately and higher. International cold-chain logistics, MoPH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted. Maintenance doses ship on a rolling basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Skyrizi specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoPH review.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Qatar? Yes, when executed through the MoPH named-patient framework with appropriate documentation.
Can Skyrizi be self-injected? For the subcutaneous maintenance dose, yes — patients or caregivers are typically trained for home use. The Crohn's IV induction is clinic-administered.
What if a local IL-23 inhibitor is available? Your physician will consider the locally registered option. Named-patient rationale applies where the specific indication, dose form, or your clinical context points to Skyrizi specifically.
Will private insurance cover this? Cash-pay is the default. Some Qatari insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Skyrizi coordination in Qatar.
Add me to the Skyrizi waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.